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Abstract
Aims: A glutathione (GSH) yeast-based biomass (Saccharomyces cerevisiae) was
used to investigate GSH stability, solubilization during gastrointestinal
digestion and GSH intestinal transport.
Methods and Results: A postgrowing procedure was applied to improve
intracellular GSH yeast content. The presence of adenine (ADE) in the
biotransformation solution (CYS-GLY-GLU mixture) and alternatively, a
glucose shot after 4-h incubation, allowed to obtain cells containing about
GSH 16–17% dcw (dry cell weight) (control 05%). Yeast samples were
subjected to in vitro gastrointestinal digestion and absorption assays employing
Caco-2 and HT29-MTX cell lines in different proportions (100/0, 70/30 and
50/50). Trials were also performed to verify intestinal cell viability.
Conclusions: At least 87% of ingested GSH is available in reduced form for
intestinal absorption. In vitro GSH transport assays indicated that GSH is
poorly absorbed (<20%). Nevertheless, studies in response to oxidative stress
induced by H2O2 demonstrated a protective role of the GSH-enriched biomass
towards intestinal cell viability.
Significance and Impact of Study: An enriched GSH yeast-based biomass has
been obtained using a postgrowing procedure. Although GSH present in
enriched yeasts is poorly absorbed by intestinal cells, this biomass showed an
intestinal local protective effect, improving cells viability when a simulated
oxidative stress was applied.
Introduction
Glutathione (GSH) is a tripeptide consisting of L-
glutamate, L-cysteine and glycine. It is found in millimo-
lar concentrations (02–10 mmol l1) in all cells, from
prokaryotes to eukaryotes, and is the most abundant low
molecular thiol in biological systems (Anderson 1998;
Ault and Lawrence 2003; Wen et al. 2005; Wang et al.
2007). Intracellularly, GSH is kept in its thiol form by
GSSG reductase, a NADPH-dependent enzyme (Anderson
1998). GSH is committed to many physiological pro-
cesses; however, its functions may be summarized in
three main topics: antioxidant, immunity booster and
defence molecule (Li et al. 2004). These characteristics
make GSH an important biochemical drug for the treat-
ment for numerous diseases, such as HIV infections, liver
cirrhosis, gastrointestinal and pancreatic inflammation, as
well as neurodegenerative diseases (Townsend et al. 2003;
Li et al. 2004). Cellular GSH concentration is markedly
reduced in response to protein malnutrition, oxidative
stress and many pathological conditions such as Crohn’s
disease, atherosclerosis and diabetes (Li et al. 2004; Wu
et al. 2004). Moreover, studies evidenced that GSH may
be therapeutically effective when given in high doses to
depleted subjects (Perricone et al. 2009).
Currently, Saccharomyces cerevisiae and Candida utilis
are the most commonly used micro-organisms for GSH
fermentative production on industrial scale, with a GSH
content of 01–1% dcw (dry cell weight) (Li et al. 2004).
They are rich sources of protein, soluble fibre, minerals
(Ca, P, K, Mg, Cu, Fe, Zn, Mn and Cr) and B vitamins,
often recommended as a dietary supplement (Yamada
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and Sgarbieri 2005; Bekatorou et al. 2006). In previous
reports (Rollini et al. 2011; Musatti et al. 2013), we
focused on the set-up of a postgrowing procedure (bio-
transformation) for GSH accumulation employing com-
mercial baker’s yeast (S. cerevisiae), while most of the
published papers concentrated on GSH accumulation in
growing cells (Li et al. 2004; Wen et al. 2005; Wei et al.
2008; Liang et al. 2009; Nisamedtinov et al. 2010). The
use of a postgrowing procedure employing commercial
baker’s yeast, a low cost cell source available on the
market, represents an alternative strategy to traditional
GSH accumulation inside yeast cell, easy and feasible for
an industrial up-scale, in particular for nutraceutical
applications.
To design an adequate dietary supplementation, it is
necessary to evaluate whether a supplement remains
intact after the digestion processes and whether it is
absorbed by the epithelium to reach the systemic circula-
tion. The in vitro combination of a simulated gastrointes-
tinal digestion and a cellular model of intestinal
epithelium to emulate absorption has been demonstrated
useful to evaluate the aspects related to the processes of
solubilization and absorption of a compound in the gas-
trointestinal tract, and hence to study the bioavailability
(Au and Reddy 2000). The term ‘bioavailability’ refers to
the fraction of an ingested compound that is solubilized
during gastrointestinal digestion and reaches the systemic
circulation (Calatayud et al. 2010). Cellular models
derived from colorectal cancers (Caco-2 and HT29-MTX)
have provided a useful tool for these studies. These cell
types have conserved parts of the programme of epithelial
differentiation, expressing many genes of differentiated
intestinal epithelial cells and maintaining in turn, the
ability to form monolayers of polarized cells once they
have reached confluence in culture (Hidalgo et al. 1989;
Lesuffleur et al. 1990).
GSH bioavailability has been studied in vivo by several
authors but up to now with discordant results. Hagen
et al. (1990) and Rahman and MacNee (1992) affirmed
that plasma GSH concentration in rats increased from
approximately 15 to 30 lmol l1 after oral GSH adminis-
tration, indicating that oral supplementation may be use-
ful to enhance GSH tissue availability. Likewise, Aw et al.
(1991) reported that in mice oral GSH intake can
increase GSH concentrations in several tissues following
its depletion. On the contrary, Witschi et al. (1992)
reported that in humans, systemic GSH availability is
negligible, and it is not possible to increase circulating
GSH to a clinical beneficial extent by an oral administra-
tion of a single dose of 3 g.
This study was aimed at obtaining a GSH-enriched
S. cerevisiae biomass and investigating GSH solubiliza-
tion and stability during gastrointestinal digestion. GSH
absorption by intestinal epithelium in vitro models was
also analysed, and trials were also performed to verify
whether GSH supplementation may be a useful strategy
to improve intestinal cell viability.
Materials and methods
Biotransformation conditions
Samples of commercial baker’s yeast (Saccharomyces cerevi-
siae) in compressed form, identified as Fala (Lesaffre, Tre-
casali-Parma, Italy), were employed. Fresh yeast cells (i.e.
1 day of storage time) were suspended (5% dcw) in 10 ml
of a biotransformation solution (identified as CYS-GLY-
GLU mixture) containing the three GSH precursor amino
acids and the following compounds (g l1): glucose 80,
sodium citrate 10, ammonium sulfate 7, monobasic potas-
sium phosphate 35, magnesium sulfate 05, cysteine 4, gly-
cine 4 and glutamic acid 4. The reaction mixture was
incubated at 28°C and 200 rev min1. CYS-GLY-GLU
mixture alone or added with adenine (ADE, 05 g l1),
adenosine (ADO, 15 g l1), dithiothreitol (DTT, 3 g l1)
or a combination of ADO/DTT or ADE/DTT were tested,
as well as a further glucose (50 g l1), after 4-h incuba-
tion with CYS-GLY-GLU mixture with or without ADE
(Table 1). Aliquots were collected at the beginning and
after 24-h incubation and then analysed for intracellular
GSH contents.
Lyophilization
Yeast samples were lyophilized to faithfully reproduce the
form usually marketed. Cells were suspended in distilled
water (20% dcw), placed in stainless steel trays as a thin
layer and then frozen at 40°C for 4 h. Cell dehydration
was carried out at 25°C and 133 Pa for 30 h in an Mini-
fast MFD 01 lyophilizer (Edwards, Crawley, UK), until a
maximum residual humidity of 5–8% was reached.
Table 1 Scheme of the biotransformation trials performed with Fala
yeast: (1), control: samples containing the CYS-GLY-GLU mixture; (2)
to (8), samples added with (g l1) adenosine (ADO), dithiothreitol
(DTT), adenine (ADE), combinations ADO/DTT and ADE/DTT, as well
as glucose shot at 4 h incubation
Trials ADO DTT ADE Glucose
(1) control – – – –
(2) + ADO 15 – – –
(3) + DTT – 30 – –
(4) + ADE – – 05 –
(5) + ADO + DTT 15 30 – –
(6) + ADE + DTT – 30 05 –
(7) control + glu – – – 50
(8) + ADE + glu – – 05 50
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Simulation of a gastrointestinal digestion.
Bioaccessibility studies
GSH standard solutions at two different concentrations
(40 and 200 mg l1, equivalent to 013–065 mmol l1)
were employed for bioaccessibility tests, as well as one
GSH-enriched yeast sample obtained from the biotrans-
formation experiments described above (trial 4, GSH
163  015% dcw), and one commercial baker’s yeast in
compressed form (control, 045  005% dcw). Yeast
samples were both lyophilized before use.
Cell culture grade water (B. Braun Medical S.A., Spain)
was used throughout the in vitro digestion assay. Enzymes
and bile salts for in vitro gastrointestinal digestion were
all purchased from Sigma: porcine pepsin (enzymatic
activity 944 U mg1 protein), porcine pancreatin (activity
equivalent to 4 9 US Pharmacopoeia specifications/mg
pancreatin) and bile extract (glycine and taurine conju-
gates of hyodeoxycholic and other bile salts). The study
was carried out using the simulated digestion process
proposed by Laparra et al. (2003) modified for a yeast
biomass.
Samples (1–3 g for yeast biomass, and 40 and
200 mg l1 for GSH solutions) were weighed, 25 ml of
cell culture grade water was added and pH adjusted to
20 with 6 mol l1 HCl. Freshly prepared pepsin solution
(10% w v1 pepsin in 01 mol l1 HCl) was added to
provide 2 mg pepsin g1 sample. Sample was made up to
30 ml with cell culture grade water and incubated in a
shaking water bath (120 strokes min1) at 37°C for 2 h.
Gastric digests were then raised up to pH 60 by drop-
wise addition of 1 mol l1 NaHCO3. The pancreatin-bile
extract mixture (04% w v1 pancreatin and 25% w v1
bile extract in 01 mol l1 NaHCO3) was added to pro-
vide 05 mg pancreatin g1 sample and 3 mg bile extract
g1 sample, and the incubation at 37°C continued for
additional 2 h. After the intestinal digestion step, pH was
adjusted to 72 by dropwise addition of 05 mol l1
NaOH. Digests were then transferred to polypropylene
centrifuge tubes and centrifuged at 10 600 9 g for
30 min at 4°C to separate the soluble (bioaccessible) frac-
tion. All trials were performed in triplicate. GSH and
GSSG contents were evaluated in the obtained bioaccessi-
ble fractions.
Intestinal cell maintenance
GSH transport through the intestinal epithelium was
investigated using Caco-2 cell line and cocultures of
Caco-2 and HT29-MTX cells. Caco-2 cells were
obtained from the European Collection of Cell Cultures
(ECACC, number 86010202, Salisbury, UK). Cell main-
tenance was performed in 75 cm2 flasks to which 10 ml
of pH 74 Dulbecco’s modified Eagle’s medium
(DMEM) with 45 g glucose l1. DMEM was supple-
mented with 10% (v v1) foetal bovine serum, 1%
(v v1) nonessential amino acids, 1 mmol l1 sodium
pyruvate, 10 mmol l1 HEPES (N-2-hydroxyethylpiper-
azine-N’-2-ethanesulfonic acid), 100 U penicillin ml1,
01 mg streptomycin ml1 and 00025 mg amphotericin
B ml1 (DMEMc).
HT29-MTX cells were kindly provided by Dr. T. Lesuffl-
eur (Institut National de la Sante et de la Recherche Medi-
cale, INSERM UMR S938, France) (Lesuffleur et al. 1990).
Cells maintenance was performed in 25 cm2 flasks to
which 5-ml medium were added, consisting of DMEM at
pH 74 containing 45 g glucose l1 and supplemented
with 10% (v v1) foetal bovine serum, 100 U penicillin
ml1, 01 mg streptomycin ml1, 00025 mg amphotericin
B ml1 and 1 mmol l1 sodium pyruvate (HT-DMEMc).
Both cell lines were incubated at 37°C, 5% CO2 and
95% relative humidity atmosphere, changing the medium
every 2–3 days. When cell monolayer reached 80% con-
fluence, cells were detached by mean of a trypsin solution
(05 mg l1) containing 022 g EDTA l1 and subse-
quently reseeded at a density of 5 9 104 cells cm2. All
reagents used were purchased from PAA Laboratories
GmbH (Germany).
Throughout the study, Caco-2 cell cultures were used
between passages 20 and 35, while HT29-MTX cells were
used between passages 40 and 50.
GSH transport assays: determination of apparent
permeability coefficients (Papp) and percentage of
transport
Transport tests were performed in 6-well plates
equipped with a polyester membrane porous support
(diameter 24 mm, pore size 04 lm; Transwell, Costar
Corp, Corning Incorporated, Corning, NY, USA); this
insert separates the well into an apical (upper) and a
basolateral (lower) compartment. Cells were seeded
(5 9 104 cells cm2) on the apical side to produce
monolayers of Caco-2 and of Caco-2/HT29-MTX (70/
30 and 50/50 proportions). Subsequently, 15-ml med-
ium (DMEMc for Caco-2 and HT-DMEMc for cocul-
tures) was added to the apical chamber and 2 ml to
the basolateral one. Cells were incubated at 37°C, 5%
CO2 and 95% relative humidity, changing the medium
every 2–3 days until cell differentiation was attained
(13–15 days postseeding). During cell growth and dif-
ferentiation in Transwell, cell monolayer integrity was
assessed daily from the sixth postseeding day onward
by measuring the transepithelial electrical resistance
(TEER) using a Millicell-ERS (Millipore Corporation,
Madrid, Spain).
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Transport assays were first performed employing GSH
standard solutions (3 and 10 mmol l1), as follows:
15 ml of the standard solution prepared in Hank’s bal-
anced salt solution (HBSS, PAA) supplemented with
20 mmol l1 pH 55 o-2-(N-morpholine) ethanesulfonic
acid (MES, Sigma, Spain) was added to the apical com-
partment, and 2 ml of HBSS with 10 mmol l1 pH 72
HEPES to the basolateral compartment. For the evalua-
tion of the apparent permeability coefficients (Papp), at
established timepoints (15, 30, 60, 120, 180 and
240 min), 300 ll was removed from the basolateral com-
partment and replaced with an equal volume of fresh
medium (HBSS with 10 mmol l1 HEPES). GSH deter-
mination was carried out in the aliquots obtained at each
time point as well as in the apical residual medium
collected at the end of the experiment.
As regards the transport studies using bioaccessible
fractions resulting from the gastrointestinal digestion,
GSH standards (3 and 10 mmol l1) or GSH-enriched
yeast samples were employed. These samples were first
inactivated by heating for 4 min at 100°C to inhibit pro-
tease activities and then cooled by immersion in an ice
bath. Glucose (final concentration 5 mmol l1, Sigma)
was then added to facilitate cell viability. If necessary,
NaCl (10 mmol l1, Panreac) was used to adjust the
osmolarity to 310  10 mOsm kg1 using a freezing
point osmometer (Automatic Micro-Osmometer Type
15 L€oser, L€oser Messtechnik, Germany). Aliquots of
15 ml of the inactivated bioaccessible fraction supple-
mented with 20 mmol l1 pH 55 MES was added to
the apical chamber and 2 ml of HBSS supplemented
with 10 mmol l1 pH 72 HEPES to the basolateral
compartment.
The apparent permeability coefficients (Papp) were cal-
culated from Equation 1:
Papp ¼ dCdt1
  VrA1C1o
  ð1Þ
where:
(dC dt1) is the flow (lmol l1 s1) determined by
the linear slope of the equation that governs the varia-
tion in the concentrations of GSH, corrected by dilu-
tion, against time;
Vr is the volume of the basolateral compartment
(2 ml);
A is the surface occupied by the cell monolayer
(467 cm2);
Co is the initial GSH concentration in the apical com-
partment (lmol l1).
Besides the calculation of the apparent permeability,
the rate of transport of bioaccessible fractions of GSH
standards (3 and 10 mmol l1) and GSH-enriched yeasts
was also evaluated, performing transport assays for 2 h,
without taking aliquots at different timepoints. For quan-
tification of GSH transport, GSH contents were deter-
mined in the acceptor (apical) and donor (basolateral)
medium collected at the end of the experiment. The per-
centages of transport to the basolateral compartment
were calculated with respect to the initial quantity of
GSH added.
During GSH cell transport trials, cell monolayer integ-
rity was evaluated by measuring: (i) TEER at several
incubation times, including the start and end of the
experiment, and (ii) Papp of the paracellular transport
marker lucifer yellow (LY), added at 100 lmol l1 con-
centration to the apical compartment in the control and
in GSH treated cells. Fluorescence of LY transported to
the basolateral compartment was measured with a fluo-
rescence microplate reader (PolarSTAR OPTIMA, BMG-
Labtech, Ortenberg, Germany) at excitation/emission
wavelengths of 485/520 nm. To evaluate any possible
interactions of LY with GSH uptake and transport, paral-
lel experiments were performed with and without para-
cellular marker, which demonstrated the absence of
interferences. The limits established for considering that
the cell monolayer integrity was maintained were as fol-
lows: TEER between 80% and 120% with respect to the
control; LY Papp ≤05 9 106 cm s1.
Effect of GSH on viability of intestinal epithelial cells
Cell viability assays were performed employing sodium
resazurin (7-hydroxy-3H-phenoxazin-3-one-10-oxide
sodium salt, Sigma). The assay is based on the ability of
viable, metabolically active cells to reduce resazurin to
resorufin and dihydroresorufin, measurable by colorimet-
ric methods. This conversion is intracellular, facilitated
by mitochondrial, microsomal and cytosolic oxidoreduc-
tases (O’Brien et al. 2000; Rocha et al. 2011).
Caco-2 cells were seeded at a density of 625 9 104
cells cm2 in 96-well plates for 5 days and subsequently
exposed for 1 h at 37°C to GSH standard solutions
(3 and 10 mmol l1, prepared in HBSS) or GSH-
enriched yeast (after in vitro digestion and thermal inacti-
vation). Afterwards, 2, 10 and 20 mmol l1 H2O2 (Panre-
ac) were added to cells and incubated for further 2 h.
Additionally, cells without pretreatment with GSH (solu-
tion or enriched yeasts) were exposed to 2, 10 or
20 mmol l1 H2O2.
After exposure, the medium was withdrawn and 150 ll
resazurin solution (10 lg ml1 in MEM) was added.
Well plates were incubated for 2 h at the same condi-
tions. 100 ll for each reaction mixture was transferred to
a 96-well plate, and resazurin reduction was measured
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colorimetrically (570 and 600 nm) using a microplate
reader (PolarSTAR OPTIMA).
Analytical procedures
Determination of intracellular yeast GSH was carried out
as reported by Musatti et al. (2013). Briefly, samples were
centrifuged (10 600 g, 10 min), and collected cells were
washed with distilled water, suspended in 05 g ascorbic
acid l1 and then thermally treated at 100°C for 10 min
to open cell structure and release GSH. After cooling in
ice bath, samples were centrifuged (10 600 g, 10 min) to
eliminate cell residues and intracellular GSH of superna-
tant fractions were determined.
GSH and GSSG identification and quantification were
carried out by HPLC (L-7000 System, Merck Hitachi,
Darmstadt, Germany) equipped with a UV detector
(210 nm), using a Purospher RP-18 endcapped column
(250 9 4 mm, Merck). The elution was performed with
25 mmol l1 NaH2PO4 (pH 28, flow rate 03 ml min1)
at 30°C. GSH and GSSG concentrations were calculated
with respect to a calibration curve of aqueous standards of
GSH and GSSG (5–50 mg l1). Standard GSH and GSSG
were purchased from Sigma, and HPLC-grade water was
obtained through a Milli-Q A10 Gradient System (Millipore
Corporation, Milano, Italy).
Statistical Analysis
One factor analysis of variance (Microsoft 2003) was
applied to detect: (i) differences in the GSH intracellular
content (% dcw) among biotransformation solutions, (ii)
viability differences of Caco-2 cells. Duncan test was
applied to detect means differences among the tested
conditions. Differences were considered significant for
P < 005.
Results
Biotransformation trials
Trials were performed by suspending yeast (5% dcw) in a
biotransformation solution containing glucose and the
three precursor amino acids involved in GSH synthesis
(CYS-GLY-GLU), as previously reported (Rollini et al.
2011). Nevertheless, because GSH biosynthesis is ATP-
dependent, some ATP-related molecules were also added
for comparison purposes (Liang et al. 2010; Musatti et al.
2013). Direct ATP addition was not chosen due to its
high cost; instead, ADE and adenosine (ADO), which can
be considered as ATP precursors, were tested. Trials were
also performed by adding DTT, an ATPase inhibitor.
As reported in Fig. 1, all tested conditions led to a sig-
nificant (P < 005) GSH increase respect to control sam-
ples with only the CYS-GLY-GLU mix (trial 1, GSH level
098% dcw). Glucose added was always consumed by the
yeast in the first 3- to 4-h incubation, leaving at the end
of the reaction a residual concentration of 5 mg glu-
cose l1 (HPLC detection limit). High GSH level was evi-
denced in the presence of 05 g ADE l1 (trial 4, GSH
163% dcw), with about a 170% increase. The incorpora-
tion of ADO, led a limited GSH increase (about 115%,
from 098 to 111% dcw, trial 2). The presence of DTT
only inhibited GSH production when ADE was incorpo-
rated (trial 6). The addition to the reaction mixture of
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Figure 1 Intracellular glutathione (GSH)
increase (% respect to control sample – trial
1) obtained after 24 h incubation in different
biotransformation conditions
(mean  standard deviation, n = 3). Letters
(a–c) on multiplot bars indicate significant
differences (Duncan test, P < 005) in GSH
increase among the tested biotransformation
conditions (1:control; 2:+ADO; 3:+DTT;
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further 50 g glucose l1 after 4-h incubation (trial 7,
GSH 167% dcw) increased intracellular GSH, similarly
to what observed when ADE was present in the medium
(trial 4). However, glucose addition when ADE was pres-
ent (trial 8) did not cause further GSH increase.
In vitro gastrointestinal digestion
Trials were first performed employing GSH standard solu-
tions (40 and 200 mg l1 comparatively). Results related
to GSH and GSSG content at the beginning of incubation
(to) and after the gastric and intestinal steps are reported
in Fig. 2. At the highest concentration (200 mg l1), a
very limited amount of GSH (up to 10%) was oxidized to
GSSG, while an oxidation of approximately 25% took
place when 40 mg GSH l1 was used. This oxidation
mainly occurred after the intestinal digestion phase and
may be due to the temperature (37°C) maintained for 4 h
and/or the neutral pH of intestinal stage.
Trials were also performed employing untreated and
GSH-enriched yeasts, both in lyophilized form, with a
GSH content of 05 and 16% dcw, respectively. At the
beginning of the digestion (t0), about 90% of the total
GSH was found bioaccessible and this value increased to
98% at the end of the digestion (data not shown). Previ-
ous trials of gastrointestinal digestion on baker’s yeast in
compressed form (not lyophilized) showed that GSH bio-
accessibility was only about 20% (data not shown). Thus,
the lyophilization process applied contributed to increase
GSH bioaccessibility. It is known that lyophilization pro-
cess damages yeast cell structure in a way that GSH can
be easily released (Musatti et al. 2013).
Gastrointestinal digestion tests produced a very limited
GSH oxidation (Fig. 3), up to 13% in the control yeast
sample and up to 7% in the case of GSH-enriched yeast.
These results confirm what previously evidenced for GSH
standard solutions.
GSH transport assays: determination of Papp and
percentages of transport
In all transport assays performed, the TEER and LY per-
meability values were maintained within the limits estab-
lished for considering the integrity of the monolayer to
be intact.
The Papp indicates the rate at which a compound
passes across the intestinal cell monolayer and is a useful
parameter for comparative studies, because values are
adjusted by the surface of the monolayer, exposure time
and concentration of the used compound. The Papp val-
ues obtained after 240 min exposure to GSH standard
solutions were as follows: 99 9 10–7 cm s1 for
3 mmol l1 and 12 9 106 cm s1 for 10 mmol l1.
Using cocultures of Caco-2/HT29-MTX (50/50 and
70/30), the Papp values for a 10 mmol l
1 GSH solution
were found similar to those obtained in Caco-2 monocul-
tures alone (81 9 107 and 70 9 107 cm s1 for
50/50 and 70/30, respectively).
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Table 2 shows the percentage of GSH transported
through Caco-2 or coculture monolayers after 120 min
exposure to either the bioaccessible fractions of GSH
standard solutions (3 and 10 mmol l1) and of enriched
yeast samples (GSH  3 mmol l1). Transport rates were
generally low (22–79%) and remained unchanged in
presence of yeast. The incorporation of HT29-MTX cells
to the monolayer produced a significant GSH transport
increase, with values reaching 7% of the GSH initially
added, in both standards and yeasts.
Effect of GSH on intestinal epithelial cells viability
Trials were performed to elucidate the possible protective
role of GSH and GSH-enriched yeast on Caco-2 cell via-
bility exposed to an oxidant (H2O2). As expected, Caco-2
cells viability decreases after H2O2 exposure, and this
decrease was found H2O2 concentration-dependent.
Figure 4 reports the results obtained by adding GSH-
enriched yeast (1 h contact time) before H2O2 addition.
For comparison purposes, pretreatments with 3 and
10 mmol l1 standard GSH solutions were also per-
formed. To be noted that a control test with yeast not
containing GSH could not be performed because all
S. cerevisiae strains have a physiological GSH content.
Results showed that pretreatment with GSH-enriched
yeast reduced intestinal cell death caused by H2O2. Future
studies will verify whether lower GSH levels in yeast
would furnish the same results here reported and will be
aimed at investigating whether other yeast components
(i.e. folates) may be involved, in association with GSH, in
reducing oxidative stresses.
Discussion
The yeast Saccharomyces cerevisiae is one of the most
studied micro-organisms, widely used in traditional fer-
mentation processes like wine, beer and bread making,
but nowadays, it also has numerous applications in other
industrial productions such as bioethanol, production of
enzymes and is employed as dried-yeast for food supple-
ment (Yamada and Sgarbieri 2005; Bekatorou et al.
2006). It has been shown that the use of yeast favours
the bioavailability of certain supplements; for example,
selenium bioavailability in a selenium-enriched yeast
increases up to 135–165% (approximately 15-fold) in
terms of tissue selenium content and 105–197% (up to
2-fold) in terms of GPx activity, compared with selenite
(Yoshida et al. 1999). The aim of the present study was
to obtain S. cerevisiae with a high GSH content for a new
food supplement formulation and to investigate the fate
of the ingested GSH.
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Figure 3 Glutathione (GSH) ( ) and GSSG ( ) concentration (mg l1) (means, n = 3) at different steps of the in vitro gastrointestinal digestion
(t0 and after gastric phase and complete gastrointestinal digestion) related to lyophilized control yeast (GSH 045  005% dcw) (a) and GSH-
enriched yeast (GSH 163  015%) (b).
Table 2 Glutathione (GSH) transported (respect to the initially
added,%) from apical to the basolateral compartment in Caco-2 cells
and co-cultures Caco-2/HT29-MTX after 120 min exposure to the bio-
accessible fractions of standard GSH solutions (3 and 10 mmol l1)
and of GSH-enriched yeast (mean  standard deviation, n = 3)
Cell line
Transported GSH (%)
Std 3 mmol l1 Std 10 mmol l1 Yeast
Caco-2 216  006 233  018 223  005
Co-culture 70/30 325  031 335  033 392  036
Co-culture 50/50 696  040 758  025 793  084
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Applying a postgrowing procedure to a commercial
baker’s yeast, already available on the market, has
increased its GSH intracellular content. This procedure
represents an alternative strategy easy and feasible for an
industrial up-scale, to the traditional growth-related GSH
accumulation. Commercial baker’s yeast generally has a
GSH content of about 05% dcw; owing to a biotransfor-
mation procedure with CYS-GLY-GLU mixture, a GSH
content of about 1% dcw is reached. The addition of ade-
nine to the mixture or glucose, after 4-h incubation,
increases GSH content up to 17% dcw, a threefold
increase respect to the physiological yeast GSH content.
The proposed product falls within the description pro-
posed by the Directive 2002/46/EC and the subsequent
Regulation 1170/2009 (Commission Regulation 2009).
This biomass can be considered as a concentrated source
of protein, soluble fibre, minerals and B vitamins as well
as a concentrated GSH source. The maximum GSH daily
supplementation in Italy, 50 mg, can only be achieved
after ingestion of 3 g of the proposed yeast.
Yeast samples were lyophilized to faithfully reproduce
the dose form usually marketed. The lyophilization pro-
cess, as demonstrated in this study, facilitates GSH solu-
bilization during its passage through the gastrointestinal
tract, and therefore, increases its availability for further
absorption through the intestinal epithelium. In addition,
gastrointestinal digestion does not negatively affect GSH
levels, only inducing a limited oxidation (7–13%). There-
fore, it can be concluded that 87–93% of ingested GSH
should be available for its absorption in the reduced
form.
There are various in vitro models for evaluating intesti-
nal absorption in humans, although the one that is most
widely used is the Caco-2 cell line. This cell line, derived
from colon adenocarcinoma, differentiates spontaneously
in culture, producing a monolayer of epithelial cells,
which shares many of the morphological and functional
characteristics of mature enterocytes (Hidalgo et al.
1989). There are studies showing that Caco-2 cells express
numerous transporters of the human small intestine, and
therefore, they are considered a good model for the eval-
uation of intestinal transport mechanisms (Maubon et al.
2007). This model is currently the most commonly
employed for in vitro study of absorption of pharmaceu-
ticals and nutrients. Numerous studies demonstrate that
it is possible to correlate the apparent permeability coeffi-
cients obtained in Caco-2 cells with the magnitude of in
vivo absorption, although the suitability of this correla-
tion depends on the nature of the transport of the com-
pound. In the present work we took into account the
study conducted by Yee (1997), according to which a
compound with a Papp in Caco-2 monolay-
ers < 1 9 106 cm s1 has low in vivo absorption (0–
20%), one with a Papp between 1 and 10 9 10
6 cm s1
has moderate in vivo absorption (20–70%) and one with
a Papp>10 9 10
6 cm s1 has high absorption (70–
100%).
The Papp values obtained in the present study classify
GSH as an element with a low in vivo absorption (<20%)
at pH 55, typical value of the duodenum. This parameter
was not found to be modified when Caco-2/HT29-MTX
co-cultures were used, model which more realistically
emulates the intestinal wall where both cell types (absorp-
tive cells and mucus secreting cells) coexist in variable
proportions depending on the part of the intestinal tract.
Furthermore, results indicate that GSH present within an
enriched yeast biomass is transported similarly a GSH
standard solution.
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Although GSH supplementation does not substantially
increase its systemic levels, GSH presence was found ben-
eficial towards intestinal cells viability. Especially in a
form of an enriched biomass, GSH could protect intesti-
nal cells when these are subjected to oxidative stress, here
simulated by the use of H2O2. The results of the present
study demonstrate an increase in viability of cells treated
with enriched yeasts when a situation of oxidative stress
is induced. Gastrointestinal tract is one of the major tar-
get for oxidative stress damage due to the constant expo-
sure to diet-derived oxidants, mutagens, and carcinogens
as well as to endogenously generated reactive oxygen spe-
cies (Couto et al. 2012). Thus, ingested GSH may have
local protective effect, acting together with GSH coming
from the biliary efflux.
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